Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

Phaeochromocytoma and paraganglioma are rare neuroendocrine tumours (NETS). They may be benign or malignant but the pathological distinction is mainly made when metastases are present. Available treatments in the form of surgery, chemotherapy, and radionuclide therapy may improve symptoms and bioche...

Full description

Bibliographic Details
Main Authors:	Druce, MR, Kaltsas, G, Fraenkel, M, Gross, D, Grossman, AB
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
by: Chrisoulidou, A, et al.
Published: (2007)

Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
by: Gueorguiev, M, et al.
Published: (2010)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
by: Grozinsky-Glasberg, S, et al.
Published: (2010)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
by: Grozinsky-Glasberg, S, et al.
Published: (2009)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
by: Eman Awad, et al.
Published: (2017-12-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
by: Mathis Wehming, et al.
Published: (2023-02-01)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
by: Gigin Lin, et al.
Published: (2018-08-01)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
by: Micol Silic-Benussi, et al.
Published: (2023-03-01)

RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
by: Beat Nyfeler, et al.
Published: (2012-01-01)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
by: Yim K-L
Published: (2012-07-01)

The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).
by: Kaltsas, G, et al.
Published: (2004)

Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)
by: Chambers, J, et al.
Published: (2010)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
by: Michael K Kiessling, et al.
Published: (2016-01-01)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
by: Gennatas Constantine, et al.
Published: (2012-09-01)

Everolimus therapy for progressive adrenocortical cancer.
by: Fraenkel, M, et al.
Published: (2013)

Everolimus therapy for progressive adrenocortical cancer
by: Fraenkel, M, et al.
Published: (2013)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
by: Druce, M, et al.
Published: (2012)

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
by: Druce, M, et al.
Published: (2012)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
by: Grozinsky-Glasberg, S, et al.
Published: (2011)

The effect of exogenous glucocorticoids on plasma catecholamines and metanephrines in patients without phaeochromocytomas.
by: Druce, MR, et al.
Published: (2011)

The Effect of Exogenous Glucocorticoids on Plasma Catecholamines and Metanephrines in Patients Without Phaeochromocytomas
by: Druce, MR, et al.
Published: (2012)

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
by: Elena Farmaki, et al.
Published: (2023-09-01)

Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling.
by: Stefanie Jeruschke, et al.
Published: (2013-01-01)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
by: James W. Wheless
Published: (2015-01-01)

Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
by: Mariarosaria Negri, et al.
Published: (2022-04-01)

Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice
by: Davoud Rostamzadeh, et al.
Published: (2022-06-01)

The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus
by: Casanovas T
Published: (2014-06-01)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
by: Jonas Dietger, et al.
Published: (2009-05-01)

The dangers of unopposed beta-adrenergic blockade in phaeochromocytoma.
by: Sheaves, R, et al.
Published: (1995)

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
by: Wei-Xiang Qi, et al.
Published: (2013-01-01)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
by: Federica Mangili, et al.
Published: (2022-06-01)

Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
by: Bomanji, J, et al.
Published: (1993)

The clinical genetics of phaeochromocytoma and paraganglioma
by: P. T. Kavinga Gunawardane, et al.

Malignant phaeochromocytoma – a challenge in diagnosis and therapy
by: Dharshini Karuppiah, et al.
Published: (2014-08-01)

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
by: Seraina Faes, et al.
Published: (2017-11-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
by: Euphemia Y Leung, et al.
Published: (2015-01-01)